Edgar Engleman has bought stock on 2 days since Dec 2017

Edgar G. Engleman is a founder and director of Bolt Biotherapeutics, Inc., a clinical‑stage biotechnology company developing immune‑stimulating antibody conjugates for cancer treatment.( He serves as an independent director on Bolt’s board and has reported insider transactions in that capacity, reflecting his ongoing governance role with the company.( Engleman is also a professor of pathology and medicine (immunology and rheumatology) at Stanford University School of Medicine, where he directs an immunology research group and oversees the Stanford Blood Center, which he founded and now serves as Medical Director.(

A leading figure in cancer immunology, Engleman has authored more than 300 scientific publications and supervised over 100–150 research trainees, many of whom have gone on to careers in academia and industry.( His laboratory’s work on dendritic cells helped provide the basis for Sipuleucel‑T (Provenge), the first FDA‑approved active immunotherapy for cancer, and he co‑founded Dendreon and several other biopharmaceutical companies, including Genelabs, Medeor, Tranquis, Cetus, and Bolt Biotherapeutics.( Beyond his academic and entrepreneurial roles, Engleman is a co‑founder and managing partner of Vivo Capital, a healthcare‑focused investment firm with offices in the U.S. and Asia.( He received his B.A. from Harvard University and his M.D. from Columbia University College of Physicians and Surgeons, followed by advanced training in internal medicine at UCSF and in biochemistry, immunology, rheumatology, and transfusion medicine at the NIH and Stanford.(

Written by Perplexity from public sources.